Key result
Treatment with the ABVD regimen yielded complete remission and progressive reversal of cardiac dysfunction in a 34-year-old female with classical Hodgkin lymphoma and atypical cardiac involvement.
Case Report (n=1)
Potentially cardiotoxic ABVD chemotherapy can be successfully used to achieve complete remission and reverse cardiac dysfunction in patients with Hodgkin lymphoma presenting with severe cardiac involvement.
Answers are grounded in this paper and cite their sources.
May support ABVD despite cardiotoxicity concerns in select Hodgkin lymphoma cases; leaves open generalizability from this single report.
Primary and secondary cardiac involvements in lymphomas are extremely rare and sometimes ill-defined entities. Thorough clinical and imagistic investigation is crucial to evaluate disease extension and its impact on cardiac function. Chemotherapeutic agents with potential cardiovascular toxicity must be cautiously employed in high risk patients. We present the case of a young female patient with classical limited stage Hodgkin lymphoma and unfavorable prognostic factors, cardiac tumor mass with significant mediastinal extension, pleural effusion and subsequent cardiac dysfunction. Potentially cardiotoxic ABVD regimen yielded complete remission and progressive reversal of parameters of cardiac function.
No takes yet. Share an insight, caveat, or question.
Butura et al. (2016) conducted a case report in Classical nodular sclerosis Hodgkin lymphoma with cardiac involvement (n=1). ABVD regimen was evaluated on Clinical and imagistic remission. Treatment with the ABVD regimen yielded complete remission and progressive reversal of cardiac dysfunction in a 34-year-old female with classical Hodgkin lymphoma and atypical cardiac involvement.
Synapse has enriched 10 related papers. Consider them for comparative context: